2002
Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome
Li B, Gruner J, Abreo F, Johnson L, Yu H, Nawas S, McDonald J, DeBenedetti A. Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome. Annals Of Surgery 2002, 235: 732-739. PMID: 11981220, PMCID: PMC1422500, DOI: 10.1097/00000658-200205000-00016.Peer-Reviewed Original ResearchConceptsCancer-related deathCancer recurrenceRelative riskBreast cancerIndependent predictorsReceptor statusProtein elevationHigh eIF4EMenopausal statusTumor sizeTumor gradeHigher cancer recurrence rateImportant independent prognostic markerKaplan-Meier survival curvesCox proportional hazards modelStage 1Progesterone receptor statusBreast cancer outcomesSmall retrospective studiesStage of diseaseEstrogen receptor statusCancer recurrence rateIndependent prognostic markerLog-rank testBreast cancer recurrence
1996
Circulating antibodies against p53 protein in patients with ovarian carcinoma
Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsOvarian carcinomaP53 antibodiesP53 autoantibodiesPositive patientsSuch antibodiesMultivariate analysisPatient disease-free survivalKaplan-Meier survival curvesSerum p53 antibodiesTumor p53 overexpressionDisease-free survivalOlder patient ageSubset of patientsTumor histologic typeOverall patient survivalSera of patientsFrequent molecular eventUnits/LFree survivalNegative patientsOverall survivalPatient ageSuch autoantibodiesAntibody levels
1995
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation